Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia

Francesco Spina, Francesca Rezzonico, Lucia Farina, Paolo Corradini

Research output: Contribution to journalArticlepeer-review

Abstract

Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). We report the first case of long-term molecular remission with continuous lenalidomide treatment in a young patient with CLL relapsed to multiple treatments. Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient-specific primers. A 20-yr-old patient with standard-risk CLL was treated with lenalidomide after multiple relapses and achieved a 4 yr long complete molecular response with minimal toxicities. Published biologic data support that lenalidomide induces an immune-mediated control of CLL, and our case suggests that long-term treatment with lenalidomide is effective at a molecular level in patients with relapsed CLL.

Original languageEnglish
Pages (from-to)340-344
Number of pages5
JournalEuropean Journal of Haematology
Volume90
Issue number4
DOIs
Publication statusPublished - Apr 2013

Keywords

  • Chronic lymphocytic leukemia
  • Lenalidomide
  • Long-term treatment
  • Minimal residual disease

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this